Article thumbnail

The Role of T Lymphocytes in Cancer Patients Undergoing Immunotherapy with Autologous Dendritic Cells

By Cláudia M. Rodrigues, Bruna F. Matias, Eddie F.C. Murta and Márcia A. Michelin
Topics: Original Research
Publisher: Libertas Academica
OAI identifier: oai:pubmedcentral.nih.gov:3095027
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. activation by high antigen dose.
  2. Altered maturation of peripheral blood dendritic cells in patients with breast cancer.
  3. (2001). Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. The Journal of Experimental Medicine.
  4. (2005). Close encounters of different kinds:dendritic cells and NK cells take centre stage. Nature Reviews Immunology.
  5. (2001). Dendritic cells injected via different routes induce immunity in cancer patients. The Journal Immunology.
  6. (2002). Development and selection of NKT cells. Current Opinion in Immunology.
  7. (1997). Effect of interleukin-10 on dendritic cell maturation and function.
  8. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide–pulsed dendritic cells. Cancer Immunology I mmunotherapy.
  9. ER-phagosome fusion defines an MHC class I cross- presentation compartment in dendritic cells.
  10. Expression of IL-10 in Th memory lymphocytes is conditional on IL-12 or IL-4, unless the IL-10 gene is imprinted by GATA-3.
  11. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.
  12. (2001). Gamma /delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunology Immunotherapy.
  13. (1993). Gamma/delta cells. Annual Review of Immunology.
  14. (2006). HPV 16/18-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecologic Oncologic.
  15. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD41 T lymphocytes.
  16. (1999). IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Therapy.
  17. (1999). Implication of γδ T cells in the human immune response to cytomegalovirus. The Journal of Clinical Investigation.
  18. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and lowdose interleukin-2.
  19. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
  20. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.
  21. (2010). Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clinical Immunology.
  22. (2001). Inflammation and cancer: back to Virchow?
  23. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells.
  24. Interferon-g and interleukin-12 pathway defects and human disease. Cytokine and Growth Factor Reviews.
  25. Interleukin-10 production by effector T cells: Th1 cells show self control.
  26. Interleukin-10 promotes the maintenance of antitumor CD8 function in situ.
  27. Interleukin-10 secretion by alveolar macrophages and monocytes in sarcoidosis.
  28. (1994). Interleukin-12: a cytokine produced by antigen-presenting cells with 1 immunoregulatory functions in the generation of T-helper cells type and cytotoxic lymphocytes.
  29. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine and Growth Factor Reviews.
  30. (2004). Mechanisms and functional significance of tumor-induced dendritic-cell defects. Nature Reviews Immunology.
  31. (1999). Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8 T cell responses to infectious agents, tumours, transplants, and vaccines. Advances in Immunology.
  32. (1996). Melanoma-specific CD4 T cells recognize nonmutated HLA-DR–restricted tyrosinase epitopes.
  33. (2002). Natural selection of tumor variants in the generation of―tumor escape phenotypes. Nature Immunology.
  34. (2000). NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunology.
  35. (2000). NKT cells: facts, functions and fallacies. Immunology Today.
  36. notch regulates IL-10 production by T helper 1 cells.
  37. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer.
  38. Peripheral blood gamma-Delta T cells in advanced-stage cancer patients.
  39. (2008). Polarized immune responses differentially regulate cancer development. Immunological Reviews.
  40. (1996). Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Research.
  41. The anticancer immune response: indispensable for therapeutic success?
  42. Tumor antigen cross presentation and the dendritic where it all begins?
  43. (1993). Tumor necrosis factor and its receptors in human ovarian cancer potential role in disease progression.
  44. (2002). Tumor necrosis factor or tumor promoting factor? Cytokine and Growth Factor Reviews.
  45. (2007). Tumor-infiltrating γδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity.
  46. (2009). Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunology Immunotherapy.
  47. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
  48. (1996). γδ and other unconventional T lymphocytes: what do they see and what do they do?